DMRA
Galecto, Inc.
There isn't enough reported data to score DMRA yet.
DMRA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
DMRA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
DMRA PE Valuation
DMRA has no meaningful PE right now: it lost money over the past year.
DMRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect DMRA's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
DMRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$12.02 | +$6.87 |
| Q2 2025 | -$13.05 | +$9.95 |
| Q1 2025 | -$15.45 | +$12.80 |
| Q4 2024 | -$18.53 | +$17.47 |
| Q3 2024 | -$18.89 | +$25.36 |
| Q2 2024 | -$23.00 | +$27.25 |
| Q1 2024 | -$28.25 | +$28.50 |
| Q4 2023 | -$36.00 | +$24.75 |
DMRA is still losing money, but far less than before: $12.02 per share over the past year, against $60.75 at its worst in late 2022.
DMRA Quarterly Revenue
DMRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.2M | -$14.6M |
| Q2 2026 | -$21.9M | -$19.6M |
| Q1 2026 | -$20.6M | -$18.2M |
| Q4 2025 | $566K | +$5.5M |
| Q3 2025 | -$2.6M | +$1M |
| Q2 2025 | -$2.2M | +$1.9M |
| Q1 2025 | -$2.4M | +$3.5M |
| Q4 2022 | -$11.5M | +$6.3M |
DMRA has burned cash in almost every quarter: −$59M over the past year, against −$12M the year before.
DMRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +36K shares |
| 1 year | +18% | +206K shares |
| 3 years | +34% | +347K shares |
| 5 years | +34% | +346K shares |
DMRA has 1M diluted shares, up 18% from a year ago.
DMRA Net Leverage
DMRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DMRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.8 | Neutral |
| Stochastic | 30.6 | Neutral |
DMRA's weekly RSI is 46 (neutral) and its Stochastic is 31 (neutral).
DMRA PE vs Healthcare Sector
DMRA has no meaningful PE right now: it lost money over the past year.
DMRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.1 | 4.3% above |
| 20 week MA | $25.9 | 15% below |
| 50 week MA | $25.7 | 14% below |
| 100 week MA | $15.5 | 42% above |
| 200 week MA | $21.2 | 4% above |
DMRA's trend is mixed: it's above three of its five weekly moving averages, and 4% above its 200-week average.
DMRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $375.0 | $344.3 | -8.2% |
| 2021 | $344.3 | $82.3 | -76% |
| 2022 | $82.3 | $29.0 | -65% |
| 2023 | $29.0 | $18.0 | -38% |
| 2024 | $18.0 | $5.15 | -71% |
| 2025 | $5.15 | $34.1 | +563% |
| 2026 YTD | $34.1 | $22.1 | -35% |
DMRA's yearly returns have swung widely, from +563% in 2025 to −76% in 2021. It's down 35% so far in 2026.